Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of carboplatin/paclitaxel with or without veliparib in newly treated advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
MOH_2017-03-29_000096Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of veliparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
veliparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2017-03-29_000096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-29_000096.